Search results
Results from the WOW.Com Content Network
By Sriparna Roy (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's ...
Dupilumab. Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6][7][8][4] It is also used for the treatment of eosinophilic esophagitis [9] and prurigo nodularis.
Contents. Ivermectin during the COVID-19 pandemic. Ivermectin is an antiparasitic drug that is well established for use in animals and people. [ 1 ] The World Health Organization (WHO), [ 2 ] the European Medicines Agency (EMA), [ 3 ] the United States Food and Drug Administration (FDA), [ 4 ] and the Infectious Diseases Society of America ...
If approved, Dupixent would be the first and only medicine in the EU indicated for EoE in this age group Paris and Tarrytown, NY, September 20, 2024. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded approval of Dupixent (dupilumab) in the European Union ...
The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, [1][2][3] and a growing list of approved medications. Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the ...
The summer surge of the coronavirus subvariants nicknamed FLiRT has given way to ever more contagious strains, a key reason behind the current high levels of COVID in California and nationwide ...
The numbers are even lower for COVID: Less than a quarter of adults and 15% of kids were up-to-date on COVID shots as of May. “They’re both nasty viruses,” says Schaffner. “The viruses can ...
The Oxford–AstraZeneca COVID‑19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus in order to prevent COVID-19 in adults aged 18 years and older. [1] The medicine is administered by two 0.5 ml (0.017 US fl oz) doses given by intramuscular injection into the deltoid muscle (upper arm).